From MarketBeat:



CVRx, Inc. experienced a surge in its stock price following a significant increase in price targets from both Lake Street Capital and JPMorgan Chase & Co. Large investors have also made substantial investments in the company, with HighMark Wealth Management LLC, Tower Research Capital LLC TRC, California State Teachers Retirement System, and Wells Fargo & Company MN all acquiring new positions in CVRx. With a 50-day simple moving average of $19.29 and a 200-day simple moving average of $17.06, the stock has experienced a steady uptick in performance. The company reported quarterly earnings of ($0.43) EPS, surpassing analyst expectations. CVRx is a commercial-stage medical device company that specializes in neuromodulation solutions for patients with cardiovascular diseases. The company’s innovative Barostim device improves symptoms for patients with heart failure, contributing to its positive stock performance.

The recent surge in CVRx, Inc.’s stock price comes after Lake Street Capital and JPMorgan Chase & Co. raised their price targets. Large institutional investors have also made significant investments in the company, contributing to its performance. With a strong 50-day and 200-day simple moving average, the company has been steadily increasing in value. CVRx is a commercial-stage medical device company specializing in neuromodulation solutions for patients with cardiovascular diseases, particularly heart failure. The company’s innovative Barostim device aims to improve symptoms for patients, contributing to the positive stock performance.



Read more: CVRx (NASDAQ:CVRX) Sets New 52-Week High After Analyst Upgrade